{"id":39905,"date":"2023-03-09T10:52:41","date_gmt":"2023-03-09T05:22:41","guid":{"rendered":"http:\/\/finservwealth.com\/glenmark-and-cediprof-announce-exclusive-distribution-agreement-in-us\/"},"modified":"2023-03-09T10:52:41","modified_gmt":"2023-03-09T05:22:41","slug":"glenmark-and-cediprof-announce-exclusive-distribution-agreement-in-us","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/glenmark-and-cediprof-announce-exclusive-distribution-agreement-in-us\/","title":{"rendered":"Glenmark and Cediprof announce exclusive distribution agreement in US"},"content":{"rendered":"<p> Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder.<\/p><div id=\"finse-4142518347\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/glenmarkcediprof-announce-exclusive-distribution-agreementus_16921491.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder. Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/glenmarkcediprof-announce-exclusive-distribution-agreementus_16921491.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/business\/glenmarkcediprof-announce-exclusive-distribution-agreementus_16921491.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder. Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/business\/glenmarkcediprof-announce-exclusive-distribution-agreementus_16921491.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Glenmark said it expects to commence distribution of the product in the US during the second half of 2023.  The drug is indicated for treatment of attention deficit hyperactivity disorder.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-39905","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2020\/200x200\/G\/GLENMARK-PHARMA_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/39905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=39905"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/39905\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=39905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=39905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=39905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}